NEW YORK (GenomeWeb News) – Toxicology and genetics lab Physician's Choice Laboratory Services has acquired the CertNDx Bladder Cancer diagnostic testing assets from Predictive Biosciences for an undisclosed amount. The CertNDx Bladder Cancer Assay is a urine-based test that uses protein biomarkers and molecular DNA analysis to detect the presence or absence of urothelial cancer in patients presenting with hematuria. It stratifies patients based on their likelihood of bladder cancer and disease progression. Predictive Bio and Arup Laboratories signed a deal a year ago to offer the test.
UK-based Microsaic Systems has signed a pre-contract commercial agreement to supply its miniature mass spectrometer, the Microsaic 4000 MiD, as an original equipment manufacturer. The agreement is for the global, exclusive marketing and sale of the instrument and the recently released MiDas interface unit as a standalone instrument for protein separation applications. Microsaic did not disclose the name of its partner, saying only that it is "a major international healthcare equipment company."
Protea Biosciences said that shares of its common stock have begun trading on the OTCQB marketplace under ticker symbol "PRGB."
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.